Yahoo Finance

• Total Revenue (Q4 2024): $165 million, a 9% sequential increase and a 10% year-over-year decrease.

• Total Revenue (Full Year 2024): $610.8 million, a 1% decrease from 2023.

• Consumables Revenue (Q4 2024): $133.5 million, down 5% year-over-year.

• Chromium Consumables Revenue (Q4 2024): $97.7 million, down 17% year-over-year.

• Spatial Consumables Revenue (Q4 2024): $35.8 million, up 61% year-over-year.

• Instrument Revenue (Q4 2024): $24.4 million, down 37% year-over-year.

• Chromium Instrument Revenue (Q4 2024): $10.9 million, down 2% year-over-year.

• Spatial Instrument Revenue (Q4 2024): $13.4 million, down 51% year-over-year.

• Services Revenue (Q4 2024): $7.1 million, up 35% year-over-year.

• Gross Margin (Q4 2024): 67%, up from 63% in Q4 2023.

• Operating Loss (Q4 2024): $49.8 million, compared to a loss of $55.2 million in Q4 2023.

• Net Loss (Q4 2024): $49 million, flat compared to Q4 2023.

• Cash and Cash Equivalents (End of 2024): $393.4 million, an increase of approximately $5 million from December 31, 2023.

• Revenue Guidance (2025): $610 million to $630 million, representing 0% to 3% growth over 2024.

• Warning! GuruFocus has detected 7 Warning Signs with TXG.

Release Date: February 12, 2025

For the complete transcript of the earnings call, please refer to the full earnings call transcript.

Positive Points

• 10x Genomics Inc (NASDAQ:TXG) launched major new products across all three platforms, receiving a tremendous customer response.

• The company introduced new products in the single-cell portfolio, offering lower prices per cell and sample, aiming to increase volumes over time.

• Spatial platform revenue grew by 33% year over year, driven by new product launches like Visium HD and Xenium Prime 5K.

• The company reorganized its sales force to better support its diverse product portfolio and customer base, aiming for full implementation by mid-2025.

• 10x Genomics Inc (NASDAQ:TXG) is focusing on expanding its biopharma segment, which currently makes up 15-20% of revenue, with plans to grow it to 50% in the future.

Negative Points

• Total revenue for 2024 was $611 million, down 1% compared to the prior year, reflecting a challenging macro environment.

• Chromium consumables revenue decreased by 17% due to lower reaction prices, impacting overall revenue.

• Total instrument revenue decreased by 37%, with spatial instrument revenue down 51% due to fewer Xenium instruments sold.

• The company faces uncertainty regarding NIH funding, which constitutes 20-25% of its revenue, with potential impacts from indirect cost caps.

• 10x Genomics Inc (NASDAQ:TXG) anticipates some lingering impact from commercial changes during the first half of 2025, particularly in the Xenium team.